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ABSTRACT 
Family cancer history is one of the most important risk factors for cancer. We investigated in 
depth the effect of family cancer history, in particular, the effects of kinship and timing on 
cancer incidence and prognosis using Swedish population-based registers.  
In Study I, we investigated how the type of kinship and sex affect the familial risk of adult 
chronic lymphatic leukemia (CLL). We found the highest relative risks for sisters of affected 
women and sons had a much higher risk than daughters if the affected parent was the mother.  
In Study II, we developed a unified model for familial risk by extending a Cox regression 
model to estimate the detailed effects of all specific kinships, using data from all family 
members simultaneously. This enabled a formal comparison of the risk to different relatives. 
We illustrated the method with applications to adult leukemia and non-Hodgkin’s lymphoma 
and found sisters of female patients had significantly higher risk for both cancers than other 
relatives. 
We next investigated how the risk pattern of four main cancers in Sweden (colorectal cancer, 
breast cancer, prostate cancer and melanoma) changes with age and elapsed time from 
diagnosis of the same cancer in a sibling. Results were presented graphically in Study III. 
For all four cancers, siblings of cancer patients had higher cancer incidence at all ages 
compared to siblings of cancer-free individuals. Relative risks were especially high in 
siblings who were young when the first cancer was diagnosed in the family. The relative risks 
were relatively constant up to 20 years after the cancer diagnosis in siblings for all cancers 
except prostate cancer, where the hazard ratio decreased steeply during the first few years. 
We found evidence that this may be due to a screening effect for prostate cancer while there 
was no evidence of a screening effect in breast cancer.  
In Study IV, we examined how family cancer history affects prognosis for patients with 
several major cancers in Sweden and we further investigated for cancers whose prognosis has 
been affected by family cancer history whether these effects are associated with histological 
type or subtype or tumor stage at cancer diagnosis. For breast and prostate cancer patients, 
family cancer history played a protective role in cancer survival, and this may be associated 
with medical surveillance of family members. However, daughters or sisters of ovarian 
cancer patients had poorer cancer survival, which is consistent with a higher proportion of 
diagnosed later stage tumors and of an aggressive histological type of ovarian cancers. 
In conclusion, our investigation in this thesis used Swedish population-based registers to 
highlight the effect of family cancer history on several outcomes, including cancer risks for 
family members and cancer patient prognosis. Our findings provide evidence that could help 
tailor screening programs for relatives of cancer patients and inform the design of genetic 
biomarker studies.  
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1 INTRODUCTION 
 
Aldred Scott Warthin, MD, PhD (1866-1931) provided the first documentation of the longest 
family cancer histories in 1913 [1] and again in 1925 [2]. This type of family history was 
updated by Weller and Hauser [3] in 1936, and Lynch [4] in 1971 and was subsequently 
described as a Lynch syndrome family [5]. Lynch syndrome is now one of the best-known 
inherited cancer syndromes among more than 200 hereditary cancer susceptibility syndromes 
[6].  
Today, where information on family cancer history is available from population based 
registers [7-11], inherited cancers can be more readily identified unlike Lynch syndrome 
which took more than 50 years. A number of studies have been carried out on the role of 
family cancer history, and a positive family history of cancer is considered as a surrogate for 
genetic susceptibility in many epidemiological studies.  
We performed in-depth analyses to understand the role of family cancer history in cancer risk 
and cancer survival, especially the effect of kinship and timing, using the Swedish 
population-based registers. The first two studies aimed to investigate relationship-specific 
familial aggregation (Study I) and developed a statistical model for estimation and 
comparison of relationship-specific familial risks (Study II). We also examined the pattern of 
familial risk changes over time, age, and elapsed time since diagnosis (Study III). In Study 
IV, we focused on the association between cancer survival in cancer patients and family 
cancer history.   
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2 BACKGROUND 
 
Cancer is the second most common cause of death in Sweden followed by diseases of the 
circulatory system [12]. Hence, understanding of cancer from various angles is crucial to 
improve health and to reduce preventable deaths. 
Figure 1 shows the percentage distribution of the ten most frequent cancer sites by gender in 
Sweden. The most common cancers are prostate cancer for males and breast cancer for 
females, representing 32.2 per cent and 30.3 per cent of all cancers for males and females, 
respectively [13]. Colorectal cancer, skin cancer (melanoma excluded), and cancer of the 
respiratory tract are the second, third, and fourth most common cancers in both males and 
females. Malignant melanoma increased the most rapidly over the last decade, 5.2 per cent 
per year for males and 5.3 per cent per year for females, compared to other malignant tumors 
[13]. 
 
 
Figure 1 The percentage distribution of the ten most frequent cancer sites, by gender. Modified from [13]. 
 
Cancers begin in gene mutations within cells. These mutations are caused by both genetic 
factors (such as inherited mutations and hormones) and environmental factors (such as 
tobacco, alcohol, diet, radiation, and infectious organisms) (see Table 1). Most cancers are 
sporadic, developed by chance or from environmental or lifestyle factors that are not passed 
from parent to child (see Figure 2) [6, 14]. Cancers with certain highly penetrant germline 
mutations are called inherited cancers, and these make up 5 to10 per cent of most common 
cancers. So far, more than 200 inherited cancer syndromes have been investigated [6], and 
examples of common inherited family cancers are listed in Table 1 [15] . A further 10-15 per 
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Table 1 Selection of known mutations and their associated with cancers. 
Mutations Genes/ Risk factors Relevant Cancer sites Refs. Identified cancer syndrome 
Germline 
mutations 
in 
 
BRCA1, BRCA2 Breast, Ovarian, Prostate, etc. [16] 
Hereditary breast and ovarian 
cancer syndrome 
p53, CHEK2 Breast, Leukemia, Brain, etc. [16] Li-Fraumeni Syndrome 
MLH1, MSH2,MSH6  Colon, Endometrial, Ovarian, etc. [16] 
Hereditary Nonpolyposis 
Colorectal cancer (HNPCC),  
Lynch syndrome 
APC Colon [16] 
Familial Adenomatous 
Polyposis (FAP) 
CDKN2 Melanoma [16] Melanoma syndrome 
Somatic 
mutations 
by 
Alcohol 
Breast, liver, oesophagus, oropharynx, 
larynx, etc. 
[17] 
 
Smoking 
Lung, bladder, stomach, , oesophagus, 
oropharynx, larynx, etc. 
[17] 
 
Diet 
Prostate, colorectal, breast, stomach, 
lung, etc. 
[18] 
 
Obesity 
Colorectal, stomach, ovarian, breast, 
non-Hodgkin’s lymphoma, etc. 
[19] 
 
Infection Stomach, lymphoma, etc. [20]  
Environmental 
Carcinogens 
Colorectal, leukemia, bladder, lung, 
stomach, etc. 
[21] 
 
 
Figure 2 Main type of cancer. Reproduced with permission from [6]. 
 
cent of cancers are referred to as “familial” and may be caused by multiple factors, such as 
chance, exposure to the same environment, inheritance of low-penetrance genes, and gene–
environment interactions. 
As cancers come from gene mutations, it is important to understand the mechanism by which 
this occurs and there are several approaches [8, 22-25]. The traditional method is clinical 
detection, in which probands and their affected relatives are identified [22, 26]. Use of twin 
data is another possible way to study the overall contribution of hereditary factors [23]. 
However, these two methods have similar difficulties, such as lack of sufficient numbers of 
cases and the possibility of selection bias [27]. An alternative way is comparing the observed 
and expected cases in families of patients or comparing the risk in those with a family cancer 
history to the risk in those with no family cancer history, in region-wide or population-based 
registers of cancer patients and family relations [8, 11, 24]. This method can have large 
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numbers at its disposal, but genetic and environmental factors are hard to separate, and it is 
also essential to have good infrastructure for the collection of high quality data to avoid 
biased estimates [28-35].  
Although newly developed technologies for identifying genes are now available [36, 37], still 
family based studies are required prior to genotyping all individuals to improve efficiency. 
Susceptibility to an inherited cancer in a family may be suspected as a result of cancers in 
close relatives, the same type of cancer on the same side of the family, young age of affected 
cancer patients, or the occurrence of genetically related cancers in one family.  
 
2.1 CANCER RISK AND FAMILY CANCER HISTORY 
A family history of cancer, especially in first degree relatives (Figure 3), is one of the most 
important risk factors of cancer occurrence.  
 
 
Figure 3 All first degree relatives of a proband (yellow colored).  
Square and circle denote male and female, respectively. 
 
Table 2 shows common cancers associated with cancer history in a family in Sweden with 
familial aggregation (as SIRs) stratified by affected type of relatives [38]. Overall, cancer 
risks in patients with affected siblings are higher than in patients with affected parents and it 
increased much higher if there are more affected first-degree relatives. Taking ovarian cancer 
as an example, women with both mother and sister affected are more than 30 times more 
likely to have ovarian cancer. 
Increased cancer risk among family members, especially first degree relatives, is likely due to 
these patients sharing more genes than the population at large, but family members also share 
habits and lifestyle to a greater degree than the general population. The increased cancer risk 
in relatives of patients can be affected by several, such as the degree of relationship with the 
affected relative [39, 40], kinship [38, 40], number of affected relatives [39-41], sex of 
relatives and sex of probands [40, 41]. The contribution of environmental factors to familial 
cancer risk can be analyzed of using spouses who shared habits and life style but not genetic  
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Table 2 Standard Incidence ratios (SIRs) with 95% confidence interval (95% C.I.) for cancer in patients by 
parental/sibling/both concordant cancer. Reproduced with permission from [38]. 
  Parents affected   Sibling affected   Both affected 
b
  
Cancer site SIR 95% C.I. SIR 95% C.I. SIR 95% C.I. 
Stomach 2.17 (1.73-2.69) 3.29 (1.41-6.52) 12.66 (1.19-46.55) 
Colorectal 
a
 1.86 (1.73-2.01) 2.87 (2.40-3.40) 5.38 (3.48-7.95) 
Lung 2.09 (1.88-2.32) 3.13 (2.53-3.84) 5.06 (2.16-10.02) 
Breast 1.84 (1.76-1.93) 2.03 (1.89-2.17) 3.27 (2.66-3.99) 
Ovary 3.15 (2.56-3.85) 4.25 (3.01-5.84) 31.64 (11.39-69.33) 
Prostate 2.45 (2.30-2.62) 4.46 (3.85-5.15) 8.62 (6.49-11.23) 
Kidney 1.87 (1.44-2.38) 4.74 (3.09-6.95)  -  
Urinary bladder 1.75 (1.45-2.10) 2.02 (1.25-3.10) 8.16 (1.54-24.16) 
Melanoma 2.62 (2.23-3.05) 2.93 (2.38-3.57) 8.95 (3.55-18.54) 
Nervous system 1.71 (1.41-2.06) 1.81 (1.32-2.43) 6.55 (1.23-19.39) 
Non-Hodgkin’s lymphoma 1.82 (1.43-2.28) 2.25 (1.44-3.35)  -  
Leukemia 1.85 (1.39-2.41) 3.02 (1.79-4.78)  -  
a. Adenocarcinoma only.  
b. Only familial triplets were diagnosed for any of the cancers listed. 
 
variants. However, cancer susceptibility among spouses because of shared lifestyle is small 
[42, 43]. Environmental factors may also be manifested by cancer risks associated with 
family size or birth order [44]. For example, family size has been studied as a risk factor for 
melanoma because of exposure to sun during holidays spent together [45-47] and for stomach 
cancer because of increased risk of infection with Helicobacter pylori in larger families [48-
50]. Lower birth weight and higher parental age are also associated with higher birth order 
and have been identified as risk factors for cancers such as breast cancer, melanoma, and 
testicular cancer [48, 51-55]. In general, lifestyles are likely to differ more between parents 
and offspring than between spouses and familial cancers in parents and offspring or in 
siblings are more likely to be due to heritable rather than environmental effects [42, 43]. 
As cancer is a common disease at older ages, cancer occurrence at a young age is more likely 
to be associated with inheritance [56-58]. Thus, age is an important factor in cancer risk, and 
both the age at diagnosis of a cancer patient and the age of their relatives need to be 
considered in the study of familial cancer risk [59]. In addition, the profile of cancer risk with 
elapsed time since the first diagnosis in a family is important with regard to improved 
counseling and optimized screening of family members of cancer patients [60]. 
Familial cancer risk is a measure of the clustering of cancer in family members, thereby 
giving the first indication of the possible involvement of heritable genes [61-63] and since it 
is the basis for clinical decisions, counseling and genetic testing for cancer risk [38, 64], it is 
deserving in-depth study. 
 
2.2 CANCER SURVIVAL AND FAMILY CANCER HISTORY  
The concordance of cancer-specific survival in family members has been studied [65-67] for 
breast cancer, prostate cancer, lung cancer, and melanoma. Children with poor parental 
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survival have an increased risk of poor survival compared with children with good parental 
survival [65, 67]. These findings might be also described by reference to genetic factors and 
environmental factors. Family members are more likely to have similar genetic variants 
associated with cancer [68-73], tumor characteristics such as tumor stage, tumor grade, and 
histological type [70-72], and response to systematic treatment [74-76]. Also, if there is at 
least one affected family member, this may affect remaining family members in terms of 
seeking medical surveillance, choice of treatment, and lifestyle after the cancer diagnosis [77, 
78]. However, there are few systematic studies about differences in survival for patients with 
a family history of cancer as compared to patients without such a family history [79-82]. 
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3 AIMS 
 
This thesis aims to provide a greater understanding of cancer etiology and prognosis in 
families affected by cancer, especially with regard to kinship and timing, in order to provide 
evidence for genetic testing, counselling and screening protocols for cancer patients and their 
relatives. The specific aim of each study in this thesis is described in the following. 
Study I: 
To examine how the type of kinship and sex affect the familial risk of adult chronic 
lymphatic leukemia. 
Study II: 
To develop a unified model for familial risk by extending a Cox regression model to jointly 
estimate and compare the effects of different kinships, using adult leukemia and non-
Hodgkin’s lymphoma as examples. 
Study III: 
To compare the pattern of changing risk of four main cancers in Sweden (colorectal cancer, 
breast cancer, prostate cancer and melanoma) with time from the index diagnosis of cancer in 
a sibling. 
Study IV: 
To investigate whether family cancer history affects the prognosis in patients diagnosed with 
twelve different cancers. 
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4 DATA SOURCES 
 
Sweden has established high-quality population-based registers, which facilitate large 
epidemiological studies in a wide range of fields.  
 
4.1 SWEDISH MULTI-GENERATION REGISTER 
This register contains all children who were born in 1932 or after and were still alive in 1961 
[83]. With the introduction of a personal identity number (PIN) in Sweden in 1947, personal 
records were established for all persons who were registered in a parish registry [84]. Then, 
children who were 15 years old or younger in 1947 were recorded along with information on 
their biological/adoptive parents. The first computerized census, on which the Multi-
Generation Register was based, was conducted in 1961. In 1991, the national registration at 
local level moved from the parish office to the local tax office and parental information is 
essentially complete for children who were alive in 1991, thanks to computerized registration. 
Children are referred to as indexes, and can be entered only once, whereas parents can appear 
in the register as many times as their number of children. Parents need not be married to be 
registered. Using this register, which contains all children–parents pairs, we can also define 
all other family relationships, of which some examples we used in this thesis are as follows. 
 Siblings are defined as full siblings when they share both biological father and 
mother. ((c1, c2) in Figure 4) 
 Siblings are defined as half siblings when they share only one biological parent. This 
type of sibling can also be divided into paternal half siblings or maternal half siblings, 
according to shared parents. ((c1, c3)  and (c2, c3) in Figure 4) 
 Siblings are defined as adoptive siblings when they share the same non-biological 
father and non-biological mother. ((c4, c5) in Figure 4)  
 
 
Figure 4 An example of two families. In a relationship between A and B, two children (c1, c2) were born. In another 
relationship between B and C, a child was born (c3). D and E adopted two children (c4, c5) with dashed line denoting 
adoption. Square and circle denote male and female, respectively. 
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 Spouse is defined as a partner with whom an individual shares at least one biological 
child. ((A, B) and (B, C) in Figure 4) 
 
4.2 CANCER REGISTER 
The Swedish Cancer Registry was established in 1958 and covers the whole population in 
Sweden [85]. It is obligatory for Swedish health care providers (physicians, pathologists and 
cytologists) to report to the registry newly detected cancer cases at clinical, morphological, 
and other laboratory examinations and at autopsies. Therefore, all tumors in an individual are 
recorded independently with personal information (PIN, sex, age, place of residence) and 
medical information (site of tumor, histological type, stage, date of diagnosis, etc.). Although 
tumors have been coded in several versions of the International Classification of Disease 
(ICD) at other times, the codes have been available as ICD-7 codes since 1958. This is 
particularly important for a cancer such as leukemia, whose classification is difficult and 
subject to change [86, 87]. Histological type has been coded in ICD-O/2 during 1993-2004 
and in ICD-O/3 from 2005. However, the old histology code according to 
WHO/HS/CANC/24.1 is also available for the whole period since 1958. Stage information 
has been collected since 2004 for all cancer sites except brain, cranial nerves, lymphoma, and 
leukemia. Gynecological tumors are coded according to FIGO (staging scheme developed by 
the International Federation of Gynecology and Obstetrics, http://www.figo.org) and the rest 
are coded according to TNM (6
th 
edition, classification system developed by the American 
Joint Committee on Cancer) [88]. 
Almost 98 per cent of the cases are morphologically verified in the Cancer Register [89]. The 
overall completeness of the Cancer Register is considered high and comparable to other high-
quality registers in northern Europe [90, 91]. 
Cancers studied in this thesis are malignant tumors that were diagnosed as the first primary 
cancer in an individual. 
 
4.3 CAUSE OF DEATH REGISTER 
The Cause of Death Register was established in 1961 and is updated annually [92]. This 
register covers all deceased persons among Swedish residents, whether the deceased was a 
Swedish citizen or not and whether the death occurred in Sweden or not, and the coverage 
has been near to 100 per cent since 1997. The main information in the register is PIN, date of 
death, and underlying cause of death, with several contributory causes of death. The cause of 
death is recorded according to the international version of the ICD codes. Swedish death 
certificates have been examined with respect to the reporting of malignant neoplasm as the 
underlying cause of death and found to be generally reliable [93-95]. We collected cancer-
specific cause of death information from the Cause of Death Register in Study IV. 
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4.4 OTHER REGISTERS 
Emigration information was used for censoring and was collected from Emigration and 
Immigration Register [96]. Socioeconomic status [37] and county of residence for matching 
variables were assembled from Censuses which were conducted at 1960, 1970, 1980, and 
1990 [97]. 
 
 
Figure 5 Linkage of database. 
 
From the linkage of these population-based registers, using personal identity number (Figure 
5), we found 11.6 million children who were born in Sweden since 1932 and about 7 million 
children of whom both biological parents were identifiable.  
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5 STUDY POPULATION AND STUDY DESIGN  
 
Figure 6 shows how we defined the study population. We identified all cancer cases of 
interest from the linked registers and referred to these as the “index persons”.  
 
 
Figure 6 A scheme for data selection. 
   
5.1 STUDY I-STUDY III 
Familial clustering was measured by comparing the cancer risk in relatives of cancer patients 
to the cancer risk in relatives of healthy persons in this thesis. For each cancer patient, we 
randomly sampled at most five controls from the population using a nested matched design 
(see Figure 6 and Figure 7). Controls should be free from the disease at the time of diagnosis 
of the corresponding case and were selected from that index’s matched risk set, matching 
factors being sex, family size, year of birth, and county of residence, thus avoiding possible 
biases due to changing cancer incidence or differential reporting in different areas. We 
counted these cancer patients and their matched controls as case probands and control 
probands, respectively. Then we recruited relatives of these probands from the study 
population and defined them as case relatives (referred to as exposed relatives or affected 
relatives) and control relatives (referred to as unexposed relatives or unaffected relatives), 
respectively. Because we analyzed relatives of probands, probands with at least one relative 
contributed to the analysis. 
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In Study I and Study II, we identified patients with a cancer of interest who were diagnosed 
during 1958-2007 and studied (adult) chronic leukemia for Study I and (adult) leukemia and 
non-Hodgkin’s lymphoma for Study II, respectively. Here, “adult” diseases meant that the 
disease was diagnosed at 15 or more than 15 years old [98]. We followed the case relatives 
and control relatives from birth or start of cancer registration, if that came later, until they 
were diagnosed with the concordant cancer or experienced other events, diagnosis of another 
malignant cancer, death, emigration or end of the study (31 December 2007), whichever 
came first.  
In Study III, we studied siblings of probands for four major cancers in Sweden, colorectal 
cancer, breast cancer, prostate cancer, and melanoma. Case probands were the patients who 
were first diagnosed with a cancer of interest as a primary in a sibship regardless of his/her 
age, during 1958-2009. Observation time began from the index’s cancer diagnosis until a 
diagnosis of the same cancer and subjects did not contribute to the risk set at any time after 
the diagnosis of another cancer, emigration, death, or the end of the observation period (31 
December 2009).  
 
Consideration of the Sampling method 
We compared cancer risks of the first degree relatives of cancer patients to the risks in first-
degree relatives of selected controls (at most five per case) rather than using the whole 
population as reference. This sampling design has several advantages. First, minimal loss of 
information is expected, as all cancer cases were selected from the population-based registers 
and all the exposed family members were included. We randomly sampled control probands 
using a nested matched design, which is useful to accommodate censoring in the disease 
experience of the proband [99]. This design also enables us to study of elapsed time (in Study 
III), from the date of the index cancer diagnosis, whereas such time cannot be well defined 
for an individual in the general population. Thirdly, the computational burden of the analysis 
is much reduced compared to using the whole population as a reference group. 
 
5.1.1 Family Cluster  
If there are more than two index persons in a family, information on some individuals may 
appear several times in the analysis. Hence, some individuals may appear more than once and 
probably in different roles in the analysis data set. Figure 7 presents an illustration of a 
matching cluster with two potential index persons (d, f). Each will have his or her own 
(matched) controls, (C1d, C2d, …, C5d) for d and (C1f,C2f, …, C5f) for f, respectively, when 
we take five controls for each case, and we include both sets of relatives in the data to be 
analyzed. Here, individual f will not only be one of the affected relatives of d but will also 
provide his own affected relatives d, e, g. In these correlated data, we defined a cluster which  
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Figure 7 An example of a matching cluster with two potential probands (d,f, yellow colored) in a case family.  
Square and circle denote male and female, respectively. 
 
comprises the combined set of all first-degree relatives of case probands who are in a family 
and all first-degree relatives of their matched control probands. Therefore, all the family 
members illustrated in Figure 7 constitute a single cluster if d and f are both cases. To 
account for the dependence in the data, we estimated variance by two different methods in 
Study II; sandwich variance estimates regarding families as independent sampling units and 
the bootstrap approach [100] using the clusters defined by the relatives of the case proband 
and their matched controls [101]. The former approach can be directly implemented in 
standard statistical software but does not consider matching nor the possible replication of 
individuals. The latter approach accommodates the dependence in the data more accurately, 
and is thus more conservative. 
 
5.2 STUDY IV 
We investigated whether there is an association between family cancer history and cancer 
survival with respect to twelve cancer sites, namely stomach, colorectal, lung, breast, ovarian, 
prostate, kidney, bladder, melanoma, (adult) nervous system, non-Hodgkin’s lymphoma, and 
(adult) leukemia. We identified all individuals who were diagnosed with a cancer of interest 
as a primary cancer in 1991-2009 (as index persons in Figure 6) and whose biological 
parents could be identified in the register. For the analysis of affected siblings, there must be 
at least two siblings in a family. After collecting information on cancer in parents or siblings, 
we divided cancer patients into two groups, familial and sporadic: familial cancer patients 
were those whose biological parents or siblings had the concordant cancer in the register and, 
all other patients were classified as sporadic. In contrast to Study I - Study III where we 
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followed relatives of cancer patients until the diagnosis of cancer, in this study we followed 
cancer patients for up to five years from the date of their primary cancer diagnosis and 
compared the survival of those with and without a family history of cancer. The choice of 
five years is common in cancer survivorship studies since most outcomes such as recurrence 
or cancer death occur within the first five years after the cancer diagnosis [102, 103]. Survival 
time was defined as the elapsed time from the date of cancer diagnosis until the date of 
cancer-specific death or the date of other censoring events (death, emigration or end of study 
on 31 December 2010), whichever came first. 
Table 3 presents the number of individuals and number of events (cancer incidence or cause-
specific death) in each study and Table 4 summarizes the follow-up and survival time (T) for 
each study. Those individuals born before the start of cancer registration cannot be followed 
fully, so that our cohorts for Study I and Study II are left truncated by the start of the Cancer 
Register, which could yield biased estimates (see Section 5.3). 
 
Table 3 Numbers of study subjects for each study. 
Study
a
 cancer 
Studied 
subjects 
case control 
probands relatives events probands relatives events 
I Adult CLL 1
st
 degree 
relatives 
9 143 26 941 167 36 354 117 088 100 
II Adult LEUK  1
st
 degree 
relatives 
22 104 66 616 308 90 456 309 313 729 
NHL 29 492 94 061 500 123 346 431 134 1397 
III colorectal 
[104] 
Siblings 
15 590 30 808 414 75 243 151 982 866 
Breast 24 362 35 418 1 681 109 674 175 750 3 607 
Prostate 14 446 20 953 1 589 63 486 103 722 2 251 
melanoma 14 452 26 125 241 71 109 129 891 383 
 colorectal 
half- 
Siblings 
2 348 3 874 32 11 214 13 861 866 
Breast 1 546 2 033 62 6 800 7 228 3 607 
Prostate 3 880 5 057 110 14 569 18 466 2 251 
melanoma 2 593 4 186 15 12 830 15 725 383 
   Parents were identifiable At least two siblings in a family 
Study
a
 cancer subjects familial sporadic familial sporadic 
   patients deaths patients deaths patients deaths patients deaths 
IV Stomach   
Cancer 
patients, 
themselves 
195 119 3 593 2 215 45 31 2 948 1 795 
Colorectal  2 563 778 21 365 6 760 861 272 17 468 5 427 
Lung  1 156 860 15 816 11 534 625 481 12 489 9 040 
Breast  4 974 403 46 299 3 969 3 062 223 37 676 3 240 
Ovarian
 
 204 82 6 173 2 343 111 58 4 897 1 824 
Prostate  6 427 392 34 956 2 636 3 897 260 27 812 2 004 
Kidney  170 53 5 805 1 783 71 24 4 565 1 413 
Bladder  417 46 8 604 1 203 129 16 6 752 905 
Melanoma  583 28 16 346 1 191 402 34 13 160 925 
Nervous 
system 
251 93 11 486 3 638 154 53 9 411 2 943 
NHL  205 42 8 820 1 827 88 25 7 000 1 428 
(adult) 
LEUK  
206 40 6 753 1 723 84 17 5 385 1 352 
a. study period is 1958-2007 for Study I and Study II, 1958-2009 for Study III, 1991-2009 for Study IV. 
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Table 4 Definition of survival time. 
Study 
Survival time (T) 
Event of interest 
Entry date, which comes later Exit date, which comes earlier 
I, II  Birth 
 Start of cancer register 
 The concordant Cancer diagnosis 
 Other cancer diagnosis 
 Emigration 
 Death 
 End of study (31 Dec, 2007) 
Concordant cancer 
III  Index’s cancer diagnosis  The concordant Cancer diagnosis 
 Other cancer diagnosis 
 Emigration 
 Death 
 End of study (31 Dec, 2009) 
Concordant cancer 
IV  Date of cancer diagnosis  Cancer-specific death 
 Death by other causes 
 Emigration 
 End of study (31 Dec, 2010) 
Cancer-specific 
death within five 
years 
 
5.3 CONSIDERATION OF BIAS 
Although registers may cover the whole population in a country, we should consider biases 
due to incomplete ascertainment [105]. Our studies are based on the several high-quality 
Swedish population-based registers which started in different calendar years: 1932 for the 
Multi-Generation Register (complete linkage of parental information was made in 1991), 
1958 for the Cancer Register, and 1961 for the Cause of Death Register. Left truncation at the 
start of the Cancer Register might result in ascertainment bias in familial risk estimates, 
especially in parents from the earlier birth cohort. Almost all cancer diagnoses of index 
persons and of their siblings are captured in the Cancer Register, except the small number of 
cases occurring before age 26 years, and this complete ascertainment will yield unbiased 
estimates of sibling relative risk [106]. By contrast, in the parents of affected children who 
were diagnosed with cancer prior to 1958, this will result in ascertainment bias but is non-
differential because of the matched design. However, Leu et al. found that familial risk 
estimates from linkage of the Swedish Multi-Generation Register and the Cancer Register 
have minimal bias, owing to left truncation of cancer diagnoses before the start of cancer 
registration [107]. Thus, we further deemed all cases included from 1958 to have good 
statistical power. As for complete linkage between parents and children made in 1991, 
estimates may be biased because of some individuals who died before 1991 and hence who 
have missing parental information. However, Leu et al. concluded that the missing familial 
links due to death had little effect, except when there was differential mortality for cases with 
and without a family history of disease [108]. Some studies confirmed this finding by 
comparing estimates from the data from 1958 and from 1991 onwards [109, 110]. 
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6 STATISTICAL METHODS 
 
6.1 SURVIVAL ANALYSIS 
Survival analysis is a tool for analyzing follow-up time (T) from a starting point, such as birth, 
until the time of events of interest. Here, the event can be either death or occurrence of a 
disease and is defined in the context of research purpose. However, it is usually difficult to 
observe the follow-up time fully until the event of interest occurs, because individuals are lost 
to follow-up due to several reasons. For example, in following individuals from birth for a 
diagnosis of stomach cancer, some will go “out of view” due to emigration, death, or the end 
of the study. We refer to such cases as censored (see Table 4).  
In the analysis of survival data, two functions are of central interest, survival function 𝑆(𝑡) 
and hazard function ℎ(𝑡) [111]. Survival function is defined to be the probability that the 
survival time T is greater than or equal to a given time t, 
 𝑆(𝑡) = 𝑃(𝑇 ≥ 𝑡). ( 1 ) 
The hazard function (also referred to as hazard rate) is the (instantaneous) rate of the failure 
for the survivors to time t during the next instant of time.  
 
ℎ(𝑡) = lim
∆𝑡→0
𝑃(𝑡 ≤ 𝑇 < 𝑡 + ∆𝑡|𝑇 ≥ 𝑡)
∆t
 ( 2 ) 
The cumulative hazard function 𝐻(𝑡) is an integration of hazard function and is associated 
with survival function as follows. 
 
𝐻(𝑡) = ∫ ℎ(𝑢)𝑑𝑢
𝑡
0
= − log 𝑆(𝑡) ( 3 ) 
where  log denotes the natural logarithm. 
 
6.1.1 Cox regression model 
The Cox proportional hazard model is the most commonly used model in survival analysis 
[112].  It can be written in two parts, the baseline hazard function of t, ℎ0(𝑡), and the effect of 
covariates 𝑋: 
 ℎ(𝑡|𝑋) = ℎ0(𝑡) exp (𝑋𝛽). ( 4 ) 
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The main assumption of this model is that the effects of covariates are multiplicatively related 
to the hazard function. Since no parametric form for ℎ0(𝑡)  is assumed, the Cox regression 
model is referred to as a semi-parametric model. Here, estimation of parameters is based on 
partial likelihood. It is essential to check the model assumption, for example, by using 
Schoenfeld’s test [113]. 
In Study I, we stratified data by kinship, sex of relatives and sex of probands and estimated 
hazard ratios (HRs) as the familial aggregation of CLL using the Cox regression model, 
where the time scale was age. HRs were adjusted for sex, year of birth, relationship to the 
proband and sex of the proband. A similar Cox model was used in Study IV to investigate 
the association of cancer survival with a concordant family cancer history as a function of 
time since cancer diagnosis and HRs were adjusted for sex, age at diagnosis, year of 
diagnosis, SES, and region of cancer diagnosis. 
 
6.1.2 A unified model (main aim of Study II) 
We expanded the Cox regression model (4) by the inclusion of several interaction terms 
allowing us to estimate relationship-specific familial aggregation of the disease of interest 
without data stratification and test the differences using formal statistical tools such as 
likelihood ratio test (LRT) or Wald test.  
We rephrased the above Cox regression model (4) as follows for the hazard rate ℎ𝑖𝑗 for j th 
record in the i th cluster (see section 5.1.1):  
 ℎ𝑖𝑗(𝑡𝑖𝑗|𝑋𝑖𝑗 , 𝑍𝑖𝑗) = ℎ0(𝑡𝑖𝑗) exp (𝛽𝑋𝑖𝑗 + 𝛾𝑍𝑖𝑗) ( 5 ) 
where  ℎ0(𝑡𝑖𝑗) is the baseline hazard at time 𝑡𝑖𝑗, 𝑍𝑖𝑗 is the binary variable for the exposure, 
and 𝑋𝑖𝑗 is the row of the design matrix describing the other covariates, including type of first-
degree relationship (parent, sibling, child), sex of the person at risk and sex of the proband 
(see Table 5). The variable defining the kinship is categorical and so can be represented by 
dummy indicators such as 𝑋1 and 𝑋2 in Table 5, where the reference group (in this case, 
siblings) depends on the chosen parametrization. In below, we will omit the subscripts, ij, for 
simplicity as long as no confusion arises.  
Including two-way interactions between X and Z in model (5) makes it possible to investigate 
the effects of kinship, sex of relatives and sex of probands in studies of familial diseases: 
1) A model to estimate HRs to different kinships is as follows: 
 
ℎ(𝑡|𝑋, 𝑍) = ℎ0(𝑡)exp (𝛽𝑋 + 𝛾𝑍 + ∑ 𝛿𝑘𝑋𝑘𝑍
2
𝑘=1
) ( 6 ) 
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where 𝑋 = (𝑋1, 𝑋2,  𝑋3, 𝑋4) as described in Table 5. For this model, log(HR), comparing 
hazard of case relatives to hazard of control relatives, is given by 𝛾 for siblings of affected 
siblings and 𝛾 + 𝛿1  for parents of affected children and 𝛾 + 𝛿2  for children of affected 
parents. 
2) A model to estimate HRs of the effects of sex of relatives is below: 
 ℎ(𝑡|𝑋, 𝑍) = ℎ0(𝑡)exp (𝛽𝑋 + 𝛾𝑍 + 𝛿3𝑋3𝑍) ( 7 ) 
where 𝛾  provides log(HR) for female relatives of affected patients and 𝛾 + 𝛿3  for male 
relatives of affected patients. 
3) A model to estimate HRs of the effects of sex of probands is below: 
 ℎ(𝑡|𝑋, 𝑍) = ℎ0(𝑡)exp (𝛽𝑋 + 𝛾𝑍 + 𝛿4𝑋4𝑍) ( 8 ) 
where log(HR) for relatives of affected female patients is obtained from 𝛾 and log(HR) for 
relatives of affected male patients is provided by 𝛾 + 𝛿4. 
We are able to test the significance of the effects of each risk factor such as type of relatives, 
sex of relatives or sex of probands by using the likelihood ratio test (LRT) because the model 
(5) is nested in each model (6-8).  
 
Table 5 Coding system for exposure and variables identifying specific familial relationships. 
  𝒁 𝑿𝟏 𝑿𝟐 𝑿𝟑 𝑿𝟒  
Exposure Case 1      
Control 0      
Relationship Parents  1 0    
Siblings  0 0    
Children  0 1    
Sex of relatives Male    1   
Female    0   
Sex of probands Male     1  
Female     0  
Specific family relation 
(proband-relative)      
Contrasts of exposed vs unexposed relatives 
for each relationship from model (9) 
Sister-sister  0 0 0 0 𝛾 
Daughter-mother  1 0 0 0 𝛾 + 𝛿1 
Mother-daughter  0 1 0 0 𝛾 + 𝛿2 
Sister-brother  0 0 1 0 𝛾 + 𝛿3 
Brother-sister  0 0 0 1 𝛾 + 𝛿4 
Daughter-father  1 0 1 0 𝛾 + 𝛿1 + 𝛿3 + 𝜑13 
Son-mother  1 0 0 1 𝛾 + 𝛿1 + 𝛿4 + 𝜑14 
Mother-son  0 1 1 0 𝛾 + 𝛿2 + 𝛿3 + 𝜑23 
Father-daughter  0 1 0 1 𝛾 + 𝛿2 + 𝛿4 + 𝜑24 
Brother-brother  0 0 1 1 𝛾 + 𝛿3 + 𝛿4 + 𝜑34 
Son-father  1 0 1 1 𝛾 + 𝛿1 + 𝛿3 + 𝛿4 + 𝜑13 + 𝜑14 + 𝜑34 + 𝜓1 
Father-son  0 1 1 1 𝛾 + 𝛿2 + 𝛿3 + 𝛿4 + 𝜑23 + 𝜑24 + 𝜑34 + 𝜓2 
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In general, by two-way and three-way products of (𝑋1, 𝑋2, 𝑋3, 𝑋4)  and inclusion of 
appropriate interactions between 𝑋𝑘𝑠 and exposure (𝑍) in model (5), all relative types can be 
considered.  
Therefore, a unified model of disease risk for first-degree relatives can be constructed as 
follows: 
 
ℎ(𝑡|𝑋, 𝑍) = ℎ0(𝑡)exp (𝛽𝑋 + 𝛾𝑍 + ∑ 𝛿𝑘𝑋𝑘𝑍
4
𝑘=1
+ ∑ 𝜂𝑘𝑘′𝑋𝑘𝑋𝑘′
𝑘≠𝑘′,𝑘<𝑘′
+ ∑ 𝜑𝑘𝑘′𝑋𝑘𝑋𝑘′𝑍
𝑘≠𝑘′,𝑘<𝑘′
+ 𝜉1𝑋1𝑋3𝑋4 + 𝜉2𝑋2𝑋3𝑋4
+ 𝜓1𝑋1𝑋3𝑋4𝑍 + 𝜓2𝑋2𝑋3𝑋4𝑍) 
( 9 ) 
where 𝜂12 = 𝜑12 = 0  because 𝑋1 = 1  for parents and 𝑋2 = 1  for children and each 
individual should be either a parent or a child of a proband. 
Model (9) allows the estimation of log(HR) comparing exposed relatives to unexposed 
relatives for all specific first-degree relationships, as presented in Table 5 (rightmost 
column). For example, log(HR) comparing risk to a sister of a case male proband to risk to 
a sister of a control male proband is 𝛾 + 𝛿4.  
Furthermore, this model (9) can be extended for familial risk for higher degree relatives 
[114]. 
As we described in Figure 7, there may be dependence in data because of two or more than 
two index persons in a family. To deal with this issue, we employed the methods of Pfeiffer 
et al. (2004) [101], using a sandwich variance estimate with families as sampling units, or the 
bootstrap approach [100] using the clusters defined by the relatives of the case proband and 
their matched controls (see section 5.1.1). With these two methods, we estimated standard 
errors and presented confidence intervals. We tested the difference in HRs between different 
kinships using the robust Wald test [115] with the sandwich variance estimates that regards 
families as independent sampling units. Detailed explanation can be found in the published 
Paper II. 
We developed the unified model in Study II and applied this method to studies of adult 
leukemia and non-Hodgkin’s lymphoma. 
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6.1.3 Poisson regression 
To unravel the effects of several time scales (such as age and elapsed time) on cancer 
incidence in case and control relatives in Study III, we used the Poisson regression model. 
The model can accommodate more than one time scale and enables the study of time 
dependent effects. To implement the Poisson regression model, we first split the records of 
age or elapsed time and aggregated the records with the same covariate patterns (exposure 
status, age/elapsed time, sex, current calendar year, and number of family members), and 
recorded the total number of events of interest and the total time that each individual spent in 
each of these intervals. The number of events (𝑦𝑖) in i th interval is assumed to follow a 
Poisson distribution with mean  𝜇𝑖 and  
 log(𝜇𝑖) = 𝑿𝑖𝛽 + ln (𝑃𝑇𝑖) ( 10 ) 
where 𝑿𝑖 represents the vector of covariates in interval i, 𝛽 represents the vector of regression 
coefficients, and 𝑃𝑇𝑖  is the total person-time that individuals spent in interval i. Various 
techniques developed for generalized linear models are applicable here. But, we should be 
careful when continuous variables are split because the choice of cutoffs for the split can be 
subjective. 
We used the Poisson regression in Study III to obtain incidence rate ratios (IRRs) comparing 
the incidence rate in case siblings and control siblings with adjustment for current calendar 
year, sex, and number of siblings in models using age as time scale. In models using time 
since the index’s diagnosis as time scale, we adjusted for current calendar year, current age, 
sex, and number of siblings. In the Poisson data, we plotted the smoothed hazard of each 
cancer from the bshazard package [116], whose function was based on B-splines and 
generalized linear mixed models [116, 117] . This package has been released in R [118].  
 
6.1.4 Flexible parametric model  
To study the pattern of changing relative risk of the event in the exposed group, we used the 
flexible parametric model rather than further splitting the data. The flexible parametric model 
[119] is fitted on the log cumulative hazard scale and used restricted cubic spline function 
[120, 121] of ln 𝑡 with k knots to estimate the log baseline cumulative hazard. 
 ln𝐻(𝑡|𝑋) = ln𝐻0(𝑡) + 𝑋𝛽 = 𝑠(ln𝑡|𝛾, 𝐤) + 𝑋𝛽 ( 11 ) 
The restricted cubic splines forced the estimate of log baseline cumulative hazard to be linear 
outside the first knot and the last knot, i.e., the minimum and maximum of the uncensored 
survival times [122]. With larger datasets (tens of thousands of observations and more), five 
or six knots are recommended to capture the reasonable shape of the log cumulative hazard 
[122]. This flexible parametric model provides an estimate of baseline hazard function. Here, 
the proportional assumption is still required to hold.  
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If the influence of covariates varies over time, the flexible parametric model can be extended 
to include interactions between covariates (𝑥𝑗) and spline function of ln 𝑡, 
 
ln𝐻(𝑡|𝑋) = 𝑠(ln 𝑡 |𝛾, 𝐤) + 𝑋𝛽 + ∑ 𝑠(ln 𝑡 |𝛿𝑗 , 𝐤𝑗)𝑥𝑗
𝐷
𝑗=1
 ( 12 ) 
where D is the number of time dependent effects, 𝐤𝑗  denotes the knots for the j th time 
dependent effect with associated a parameter, 𝛿𝑗.  
In Study III, the changing cancer risks with age and elapsed time are presented graphically 
as HRs. These were estimated by using five knots in spline for cumulative baseline hazard 
and two knots for time dependent effect using the stpm2 package [123] in Stata (Statacorp, 
College Station, TX) [124].  
 
6.2 MULTINOMIAL LOGISTIC REGRESSION 
We used multinomial logistic regression to study the relationship between covariates and an 
outcome with more than two categories [125]. Assume there are three categories in the 
outcome variable, coded 0, 1, 2 for Y, with 0 denoting the reference outcome. If we are 
interested in the model with a dichotomous covariate 𝑥 , such as family cancer history 
variable in Study IV, we have the following regression model: 
 𝑃(𝑌 = 𝑗|𝑥) =
1
1 + ∑ exp (𝑥𝛽𝑘)
2
𝑘=1
 for j = 0 ( 13) 
 𝑃(𝑌 = 𝑗|𝑥) =
exp (𝑥𝛽𝑗)
1 + ∑ exp (𝑥𝛽𝑘)
2
𝑘=1
 for j = 1 or 2 ( 14) 
With this, we can compute the odds ratio of the j th category (OR𝑗) as below: for j ∈ {1, 2} 
 
OR𝑗 =
𝑃(Y = 𝑗|𝑥 = 1)/𝑃(Y = 0|𝑥 = 1)
𝑃(Y = 𝑗|𝑥 = 0)/𝑃(Y = 0|𝑥 = 0)
  ( 15) 
OR𝑗  represents the odds ratio of the category 𝑗 relative to the reference (Y=0) within those 
with x=1 compared to those with 𝑥 = 0. 
Multinomial logistic regression was implemented in Study IV to investigate the association 
between tumor stage having multiple categories and family cancer history. Here, the tumor 
stage is treated as outcome and the family cancer history is considered as the main exposure, 
while adjusting for sex, age at diagnosis, year of diagnosis, socio-economic status, and region.  
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7 RESULTS AND INTERPRETATION 
7.1 STUDY I : HIGH RISKS OF FAMILIAL CLL FOR SPECIFIC RELATIVES: 
SIGNPOSTS FOR GENETIC DISCOVERY? 
7.1.1 Results 
Overall familial aggregation of CLL is HR=7.7 (95% confidence interval (6.00-9.87)) 
consistent with those reported by Goldin et al. [126], and specific familial aggregations for 
each type of relative are presented using a pedigree diagram in Figure 8. The highest familial 
aggregations were for same-sex siblings of both female probands (28.52, 95% C.I. (3.43-
237.26)) and male probands (14.60, 95% C.I. (5.71-37.30)). Although we excluded twins 
from sibling pairs to remove the latent genetic confounder, little or no difference was 
estimated in the results. Sons had a much higher risk than daughters, especially if mother was 
affected (23.51, 95% C.I. (6.92-79.90)). To assess the potential impact of shared 
environmental exposure, we studied spouses but found no evidence of an increased risk of 
CLL in the spouses of cases. 
 
Figure 8 Pedigree diagram presenting the hazard ratios with 95% C.I.s of CLL for different family members of male and 
female probands. The estimates from a function of age and are adjusted for sex, birth cohort, relationship to the proband and 
sex of the proband. 
 
7.1.2 Interpretation 
Adult leukemia and childhood leukemia are considered as different disease entities. 
Childhood leukemia is mostly of the acute lymphatic type, while the majority of adult 
lymphatic leukemia cases are chronic. There was no evidence of familial effect in childhood 
leukemia [98, 127, 128]. In addition, the response to treatment is dramatically different for 
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childhood and adult leukemia, with a very high cure rate for childhood leukemia [129] and a 
poor prognosis for adults [130, 131]. We observed the striking familial aggregation for CLL, 
which is consistent with an inherited genetic effect that has been proposed [132, 133], with 
evidence accumulated from family studies and linkage studies [104]. Recent association 
studies have identified common variants associated with susceptibility to CLL [134-137], but 
these may only account for a small proportion of the genetic risk [137, 138]. The lack of 
increased risk for spouses in our data suggests that shared adult environment is not an 
important factor for familial CLL. Our observation of high risks for same-sex siblings might 
call for further work to assess the possible contribution of childhood environment. We 
propose that in studies of familial CLL, consideration of sex and kinship may be crucial to the 
genotyping of informative subjects for genetic discovery. 
 
7.2 STUDY II : A UNIFIED MODEL FOR ESTIMATING AND TESTING FAMILIAL 
AGGREGATION 
7.2.1 Results 
We applied extended Cox regression models, (5)-(8) and the unified model (9) described in 
section 6.1.2, to studies of familial cancer risk with respect to adult leukemia and non-
Hodgkin’s lymphoma, from Swedish population registers. Table 6 presents results from the  
  
Table 6 Estimated hazard ratios with 95% confidence intervals for risks of adult leukemia in family members. 
Adult Leukemia  HR and 95% C.I.
a
 P-value 
b
 Applied model 
Overall  2.00 (1.75-2.28)  (5) 
Relationship Parents 1.91 (1.57-2.32)  
(6) Siblings 3.07 (2.19-4.31)  
Children 1.80 (1.45-2.24) 0.03 
c
 
Sex or relatives Male 2.09 (1.75-2.49)  
(7) 
Female 1.89 (1.54-2.32) 0.46
 c
 
Sex of probands Male 2.05 (1.72-2.44)  
(8) 
Female 1.93 (1.57-2.39) 0.69
 c
 
Specific family 
relationship 
(proband-relative)    
Sister-sister 5.35 (2.72-10.54) Ref. 
(9) 
Daughter-mother 1.37 (0.83-2.27) <0.01 
Mother-daughter 1.61 (0.93-2.80) <0.01 
Sister-brother 2.03 (0.91-4.50) 0.07 
Brother-sister 2.34 (1.09-5.05) 0.11 
Daughter-father 1.92 (1.26-2.93) 0.02 
Son-mother 2.02 (1.40-2.91) 0.02 
Mother-son 1.96 (1.30-2.95) 0.04 
Father-daughter 1.56 (0.99-2.48) 0.02 
Brother-brother 3.10 (1.77-5.41) 0.25 
Son-father 2.13 (1.52-2.99) 0.10 
Father-son 1.95 (1.35-2.83) 0.10 
a. HRs and 95% C.I.s from a function of age and with adjustment for kinship, sex of proband, and sex of relative. 
b. Based on the robust Wald test, to test the difference in HRs of kinships where the HR of sisters of female probands as 
reference. 
c. Based on the LRT, to test significance of difference in HRs. 
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adult leukemia analyses. The overall HR of adult leukemia was 2.00 with 95% C.I. (1.75- 
2.28) based on the sandwich variance and 95% C.I. (1.64-2.39) based on the bootstrap 
variance. We found familial risks to be higher for siblings (3.07, 95% C.I. (2.19-4.31)) than 
for parents (1.91, 95% C.I. (1.57-2.32) and children (1.80, 95% C.I. (1.45-2.24), and this 
observed difference was statistically significant based on the likelihood ratio test (LRT) 
(p=0.03). By implementing our unified model, we found that sisters of female probands have 
a significantly higher risk than any of the other relatives except brothers (of female probands) 
and a higher risk than mothers or daughters of male probands (Table 6). Graphical 
presentation with a pedigree diagram is presented in the published Paper II. Additional 
results of non-Hodgkin’s lymphoma are also published in Paper II. 
We re-analyzed the CLL data, from Study I [139], using the unified model, and found no 
clear evidence of sex-linked genetic susceptibility [140] as the risk to daughters was not 
significantly different to the risk to sons of affected mothers (p=0.13) but we detected a 
higher risk for sons (compared with daughters) of affected fathers (p=0.04) (see Figure 9).  
 
 
Figure 9 Pedigree diagrams showing the hazard ratios of adult chronic lymphatic leukemia for different family members of 
male and female probands. Squares and circles denote male and female, respectively. The estimate marked with an asterisk 
(*) are significantly different than the reference (risk to sons of male probands who are represented by a box with dotted 
borders). Significance level is 0.05. 
 
7.2.2 Interpretation 
Unified model 
To investigate how familial risk of disease varies with kinship, we proposed a unified model 
using an extended Cox regression model by inclusion of interaction terms using all data 
simultaneously. This allowed us to formally test and compare the difference of kinship-
specific familial aggregation. Our method enables the effect of different kinships to be 
estimated and offers an improvement over traditional epidemiological investigations, which 
have relied on stratifying the data and conducting many separate analyses. However, our 
 29 
 
method requires a large sample size because we are interested in the effect of the interaction 
terms, but this may present computational challenges in the variance estimation from the 
bootstrap approach. In our data, confidence intervals obtained from robust sandwich 
estimation and bootstrap are similar although the bootstrap approach is preferable because it 
considers dependence in data more accurately [101]. 
Application to adult leukemia and non-Hodgkin lymphoma studies 
The ability to model all relationships within the family may offer deeper insight into the 
potential genetic and environmental factors underlying familial clustering of disease and 
provide a more refined tool for genetic counseling of family members, where the kinship with 
the affected family member is considered.  
We confirmed previous findings of familial aggregation of adult leukemia and non-
Hodgkin’s lymphoma: both are well known as familial cancers [38, 141, 142], in which 
higher sibling risks compared to risks from parents may be explained by shared childhood 
environment as well as involvement of recessive susceptibility [38], and sex-specific and 
kindred-specific familial risk of NHL from simple standardized incidence ratios are 
reconfirmed [141]. The significantly increased risk in siblings of the same sex (particularly 
sisters) suggests that shared environmental risk factors between family members account for 
at least part of the risk [143, 144].  
 
7.3 STUDY III : PATTERNS OF CHANGING CANCER RISKS WITH TIME SINCE 
DIAGNOSIS OF A SIBLING  
7.3.1 Results 
Absolute risk of cancer by age 
Case siblings had higher cancer incidence than control siblings for all cancers at all ages, with 
the exception of prostate cancer, for which no conclusions could be drawn for siblings 
younger than 40 years because no events occurred. Graphical presentation and additional 
details can be found in the published Paper III. 
Overall relative risk of cancer 
Overall familial aggregation of each cancer was found to be consistent regardless of the time 
scale, age, or elapsed time. The incidence rate ratio (IRR) with 95% confidence interval (95% 
C.I.) was 2.41 (2.14-2.71) for colorectal cancer, 2.37 (2.24-2.52) for breast cancer, 3.69 
(3.46-3.93) for prostate cancer, and 3.20 (2.72-3.76) for melanoma. These findings were 
consistent with other studies [145-149].  
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Full siblings Half siblings 
Colorectal cancer 
(a)  (b)  
  
Breast cancer 
(c)  (d) 
  
Prostate cancer 
(e)  (f)  
  
Melanoma 
(g)  (h)  
  
 
Figure 10 HRs with 95% C.I.s (solid lines with gray-shaded invervals) comparing siblings of cancer patients and siblings of 
matched controls where time scale is time since diagnosis. The straight line at hazard ratio=1 corresponds to the reference 
group, control siblings. Left column for full siblings and right column for half-siblings. 
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Relative risk of cancer by age 
The relative risk was significantly higher in case siblings at all ages. Younger siblings had the 
highest IRR for colorectal cancer, breast cancer, and prostate cancer, and the IRRs for each 
cancer decreased with age, with melanoma having the most gradual decrease and prostate 
cancer decreasing steeply at age 50-55, with relatively slow decrease thereafter. The 
increased relative risk in case siblings was relatively stable in older ages. Figures and 
additional results are published in Paper III. 
Relative risk of cancer by time since diagnosis of the index case 
The risks in case siblings were significantly higher than in control siblings for up to 20 years 
after the index person’s diagnosis. The increased risk was relatively stable over time for 
colorectal cancer, breast cancer, and melanoma, whereas prostate cancer illustrated a steeply 
decreasing trend during the first few years and was stable thereafter (see (e), left column in 
Figure 10). 
Screening effects for breast cancer and prostate cancer 
We probed the effect of screening on siblings of prostate cancer patients by comparing the 
risk shortly after index diagnoses in the periods pre- and post- 1997, the year of introduction 
of prostate-specific antigen (PSA) testing for prostate cancer in Sweden [60, 150]. We found 
that the incidence rate in brothers of prostate cancer patients diagnosed after 1997 increased 
right after the index diagnosis and reduced thereafter, a typical pattern of a “screening effect”, 
whereas no such pattern was apparent before 1997 (see Figure 11). A similar comparison 
was conducted for breast cancer pre- and post-1990, the year of nationwide implementation 
of mammography screening for breast cancer in Sweden [60, 151], but no such a trend of a 
screening effect was observed after the cut-year. Additional figures and detailed information 
are published in paper III. 
 
 
Figure 11 Cancer incidence rate with 95% C.I.s in brothers of prostate cancer patients (solid lines with gray-shaded intervals) 
and their matched controls (dashed lines) with adjustment for age at the time of brother’s prostate cancer diagnosis. 
 
 
 32 
Analyses in adoptive or half-siblings 
We also analyzed familial risks in adopted or half siblings to support interpretation about our 
observed patterns. However, despite a reasonable number of adoptees (n=9,894) and cancer 
events (n=129, 55, 38, 38 of breast, prostate, colorectal, and melanoma, respectively), we 
found only one pair of adoptive sisters where both had breast cancer and no concordant 
sibships for the other cancers, and thus further investigation with adoptive siblings was not 
able to be conducted.  
In half-siblings, overall relative risks were much lower than for full siblings, 1.97 (1.11-3.48) 
for colorectal cancer, 1.12 (0.90-1.39) for breast cancer, 1.55 (1.14-2.12) for prostate cancer, 
and 1.51 (0.79-2.89) for melanoma and some IRRs were not significant and had wide 
confidence intervals because of lack of statistical power. However, we found a significantly 
higher (though lower than for full siblings) relative risk of prostate cancer in men during the 
first few years after a step-brother’s diagnosis (see (f), right column in Figure 10).  
 
7.3.2 Interpretation 
In this study, we focused on siblings rather than parent–child relationships. Since siblings are 
more likely to be contemporaries, a health professional is able to provide helpful and realistic 
advice for siblings at risk. Also, much less susceptibility to bias was expected in studying 
siblings than parent–children pairs.   
The high familial risks at younger ages for colorectal cancer was consistent with the familial 
risk of tumors related to hereditary non-polyposis colorectal cancer which is associated with a 
young age at onset [152-155]. Also, the high familial aggregation of breast cancer at younger 
ages is consistent with reports of a higher prevalence of mutations in the BRCA1/BRCA2 
genes in young patients and a high probability of the same gene mutations in their sisters [156, 
157]. The decreasing pattern in the first five years after a brother’s cancer prostate cancer 
may be related to the screening effect, which is consistent with a lead-time bias from 
opportunistic screening of family members [158], and further extends to half-brothers. In 
contrast, no evidence of screening effect for breast cancer was observed because of its shorter 
lead time, similar in magnitude to the screening invitation interval in Sweden [159, 160].  
The graphical presentation of trends regarding the change of cancer risk in siblings from the 
first cancer diagnosis in a sibling over two important time scales (age and time since 
diagnosis) can help in understanding and interpreting the change in familial risk over time. 
Siblings of cancer patients continue to be at increased risk, even after many years, and thus 
continued, and perhaps more frequent, screening may be important in this subpopulation. 
 
 33 
 
7.4 STUDY IV : DIFFERENCES IN SURVIVAL FOR PATIENTS WITH FAMILIAL 
AND SPORADIC CANCER 
7.4.1 Results 
We found that a family cancer history of a concordant cancer played a protective role for 
cancer survival in patients with breast cancer, prostate cancer or leukemia: the hazard ratio 
(HR) was 0.88 (95% confidence interval 0.81-0.96) for breast cancer, 0.82 (0.75-0.90) for 
prostate cancer, 0.70 (0.54-0.92), for leukemia. We also found that stomach cancer patients 
who had an affected parent had better survival than sporadic cancer patients, 0.82 (0.68-0.99). 
In contrast, familial cancer patients had a worse prognosis for patients with ovarian cancer 
and nervous-system cancer: 1.20 (1.01-1.43) and 1.24 (1.05-1.47), respectively. These HRs 
are presented in Figure 12 stratified by the affected relative. 
For breast cancer, prostate cancer and leukemia, the protective effect was strongest in 
younger patients and in breast cancer patients with an affected sibling or leukemia patients 
with an affected parent. Familial ovarian cancer patients with an affected sister diagnosed at 
younger ages had the highest relative risk, 1.75 (1.23-2.49).  Additional details can be found 
in the manuscript for Study IV. 
 
Figure 12 HRs with 95% C.I.s comparing survival of familial cancer patients to survival of sporadic cancer patients  
over five years after the cancer diagnosis. The estimates are adjusted for sex, age at diagnosis, year of diagnosis, SES, and 
region of cancer diagnosis.    
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For the six cancers which had any significant association in Figure 12, we further examined 
the potential explanation for the differential survival varying with cancer sites by the 
proportion of aggressive histological type/subtype in familial cancer patients, differential 
survival within histological type/subtype, and stage at diagnosis. Table 7 presents results of 
breast cancer and ovarian cancer from our data. Among breast cancer patients, most had a 
ductal breast cancer and ductal breast cancer patients with family cancer history had better 
cancer survival than sporadic ductal breast cancer patients. Serous ovarian cancer is quite 
aggressive and has a familial component but no survival difference was found in familial 
ovarian cancer patients and sporadic ovarian cancer patients. However, we observed that 
mucinous ovarian cancer patients with family cancer history had twice the risk of death of 
sporadic cancer patients. Family history of prostate cancer was associated with a reduction of 
11 per cent in the odds of getting a T3 tumor (Table 8). No significant association was found 
with nodal involvement (N) nor with metastasis (M). We observed a large and significant 
increase in the odds of higher FIGO stages versus the lowest stage for ovarian cancer, odds 
ratio ranging from 2.52 to 3.22. Further details can be found in the manuscript for Study IV. 
 
7.4.2 Interpretation 
We have demonstrated a different role of family cancer history in cancer prognosis 
depending on the cancer site: a protective effect for stomach cancer, breast cancer, prostate 
cancer, and leukemia but a poorer prognosis for ovarian cancer and nervous system cancers. 
No association was found for lung cancer, kidney cancer, bladder cancer, melanoma, or non-
Hodgkin’s lymphoma.  
 
Table 7 Results related to histological type/subtype : Overall 5-year mortality rate (column 3), distribution of histology by 
family cancer history among patients (columns 4-8) and hazard ratios comparing survival of familial cancer patients to 
survival of sporadic cancer patients over 5 years (column 9). 
Cancer 
sites 
histology 
5-year mortality 
rate per 1000 
person-years 
n.patients 
HR & 95% C.I.
 c
 
sporadic (%) familial (%) P b 
Breasta all 19.8 (19.2-20.4)       
 Ductal 19.5 (18.7-20.2) 27723 (67.9) 4787 (67.3)  0.86 (0.76-0.96) 
 Lobular 14.7 (13.3-16.2) 5240 (12.8) 1000 (14.1) * 0.99 (0.75-1.30) 
 Others 24.2 (22.7-25.8) 7865 (19.3) 1330 (18.7) 0.02 0.88 (0.73-1.06) 
Ovarian all 114.8 (110.1-119.7)       
 Serous 144.3 (136.2-152.8) 2425 (43.3) 154 (54.8) * 1.06 (0.83-1.34) 
 Mucinous 85.7 (73.3-100.2) 523 (9.3) 16 (5.7)  2.09 (1.09-3.98) 
 Endometrioid 70.8 (61.5-81.5) 694 (12.4) 38 (13.5)  0.99 (0.50-1.97) 
 Clear-cell 90.9 (75.0-110.2) 315 (5.6) 13 (4.6)  1.05 (0.37-3.02) 
 
Adenocarcinoma 
NOS 
143.0 (129.5-157.9) 868 (15.5) 31 (11.0)  0.80 (0.44-1.45) 
 Others 75.2 (65.8-85.9) 778 (13.9) 29 (10.3) 0.002 1.36 (0.73-2.52) 
a. female only. 
b. Chi-square test for difference in proportions between familial cancer patients and sporadic cancer patients. 
* Histological type where difference occurred between familial cancer patients and sporadic cancer patients. 
c. HRs with 95% C.I.s with adjustment for sex, age at diagnosis, year of diagnosis, SES, and region of cancer diagnosis. 
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Table 8 Observed counts of familial cancer patients and sporadic cancer patients by tumor extent (T) categories for prostate 
cancer or FIGO categories for ovarian cancer. 
By TNM T1 T2 T3 T4 P 
b
 
Prostate Sporadic (ref.) 11220 6129 2860 384  
 Familial 3418 1769 734 130 0.001 
 OR & 95% C.I.
 a
  
0.97 
(0.91-1.04) 
0.89 
(0.81-0.97) 
1.14 
(0.93-1.39) 
 
By FIGO I II III IV P 
b
 
Ovarian Sporadic (ref.) 565 176 827 265  
 Familial 13 11 45 18 0.01 
 OR & 95% C.I.
 a
  
2.79 
 (1.21-6.40) 
2.52  
(1.33-4.79) 
3.22  
(1.52-6.79) 
 
a. ORs with 95% C.I.s for familial cancer patients vs sporadic cancer patients are adjusted for sex, age at diagnosis, year of 
diagnosis, SES, and region of cancer diagnosis. 
b. Chi-square test for difference in proportions between familial cancer patients and sporadic cancer patients. 
 
Patients with a family history of breast cancer may derive a survival benefit from positive 
medical surveillance and increased awareness in breast cancer patients [160]. Familiality of 
lobular breast cancer [161-163] and its better prognosis compared to survival of other types 
of breast cancer [164] could partly explain the protective effect. 
Prostate cancer patients with an affected father or brother are more likely to seek medical 
attention. We showed in Study III that the cancer incidence in full or half- brothers of 
prostate cancer patients increased significantly right after a cancer diagnosis in a brother, 
providing evidence that the introduction of PSA testing may contribute to the increased risk 
[165]. Thus familial prostate cancer patients have higher probability of early detection thanks 
to opportunistic screening such as PSA testing [150], which contributes to a protective role of 
family cancer history in cancer prognosis.   
We observed several factors to support the poor prognosis in women with a family history of 
ovarian cancer. Young ovarian cancer women with an affected sister had a higher risk of 
death in the five years after the cancer diagnosis, which may be related to germline mutations 
relevant to ovarian cancer [166]. Serous ovarian cancer was more frequently detected among 
familial ovarian cancer patients [167], and had a poorer prognosis than other histological 
types [79, 168]. In our data, patients with familial mucinous ovarian cancer had increased risk 
of death, possibly suggesting germline mutations related to prognosis or therapy response. In 
addition, higher FIGO stage tumors detected in familial ovarian cancer patients may be due to 
lack of diagnostic testing sufficiently accurate to identify early-stage ovarian cancer [169]. 
Familial cancer patients with cancer of the nervous system had a poorer outcome than 
sporadic cancer patients, the effect being highest in patients with gliomas of uncertain origin 
histological type. Among leukemia patients with a family history of leukemia, lymphatic 
leukemia whose prognosis was better than other subtypes [170] was more likely to be 
observed [171-173]. This may contribute to the protective effect of family cancer history. 
We provide evidence that family cancer history is a prognostic factor for cancers at some 
sites and that histological type of cancer also has some prognostic value. As we noted for 
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leukemia in Study I, the strong evidence of more aggressive ovarian cancers in sisters and 
daughters of ovarian cancer patients may be informative for genetic counseling and help to 
guide further molecular or genetic investigations. 
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8 CONCLUSIONS AND FUTURE PERSPECTIVES 
 
This thesis presents in-depth analyses of familial cancer using the Swedish population based 
registers to address to the following questions: what is the risk to specific relatives where a 
family member is diagnosed with cancer? how should relatives of cancer patients perceive 
their risk at different ages? should relatives be considered at higher risk for their remaining 
life time? does family cancer history play a role in cancer survival?  
We examined how the type of kinship and sex affect the familial risk of adult chronic 
lymphatic leukemia. We developed a unified model to address this question in general by 
extending the Cox regression model to include interaction terms that enable estimation and 
formal comparison of family members. For four of the main cancers in Sweden (colorectal 
cancer, breast cancer, prostate cancer and melanoma), we presented the pattern of changing 
cancer risk with time since the first diagnosis in a sibling. Lastly, we investigated the 
association between family cancer history and cancer patient survival with respect to twelve 
familial cancers. 
The main conclusions from the four studies are as follows, 
 Familial aggregation in chronic lymphatic leukemia is high and it varies by sex and 
kinship: the highest familial risk is in sisters of affected women, followed by sons of 
affected mothers. 
 No increased risk of CLL was found in the spouses of case probands suggesting that 
shared adult environment may not contribute to familial risk.  
 Familial risks to all family members can be jointly estimated and compared with 
formal statistical tests using a unified model that accommodate correlation in the data. 
 In four major cancers in Sweden, colorectal cancer, breast cancer, prostate cancer and 
melanoma, the increased cancer risk in siblings persists for up to 20 years after the 
index cancer diagnosis in the family. Moreover, the risks are higher if an individual is 
young when his or her sibling is firstly diagnosed with cancer. 
 Brothers of prostate cancer patients have slightly higher relative risks in the first few 
years after the index diagnosis in the family, which may be related to the effect of 
opportunistic PSA screening. 
 Cancer survival is associated with a concordant family cancer history for some cancer 
sites: stomach, breast, prostate, ovarian, nervous-system and leukemia. 
 Differences in histological type/subtype contributed to differential cancer survival for 
familial and sporadic cancers. 
 The poor prognosis for sisters and daughters of ovarian cancer patients is associated 
with multiple factors, including familiality of aggressive histological type and higher 
tumor stage at cancer diagnosis. 
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The unified model developed in Study II can estimate kinship-specific familial aggregation 
without the need for data stratification. The model can be readily extended to higher degree 
relatives, although it needs further development to derive variance estimators to properly 
account for matching and familial correlation considering the different layers of dependence 
in the data. Today, there have been many studies of the most complex human diseases and 
their association with genetic variants, such as cancer, diabetes, and Alzheimer’s disease 
[174, 175]. We believe that our unified model has potential for application to many areas, not 
only in cancer studies but also in studies of other diseases such as autism [176] or psychiatric 
problems [177], offering an improvement over traditional epidemiological investigations. A 
deeper understanding of the role of kinship should be given priority in the design of genetic 
biomarker studies. 
It is important to know if/how the risk of disease changes over time as well as describing 
overall or lifetime increased risk. Study III in this thesis unraveled the effects of age and 
elapsed time on cancer risks in siblings. The resulting information which was presented 
graphically provides evidence for whether or when family members should undergo 
screening and/or genetic testing. We can also observe an evidence of the effect of screening 
especially for prostate cancer. Further linkage of family data to known risk variants or 
identified susceptibility markers [178] may improve risk stratification and characterize 
subpopulations for targeted screening.  
Family cancer history is a well-known and an unavoidable risk factor for cancer. This thesis 
studied family cancer history from various angles and found that it is associated  not only 
with cancer risk in relatives but also with cancer survival in patients for some cancer sites and 
even in cancer patients with specific histological types. This being so, it is important to 
understand the role of family cancer history systematically. For example, relatively high 
familial risks in sisters of affected female siblings for several hematological malignancies, 
including adult (chronic) leukemia, and non-Hodgkin’s lymphoma, reflects the possible 
contribution of shared genetic variants [179]. Thus, it is important to consider sex and kinship 
in selecting informative subjects to identify such genes. As the high familial aggregation can 
also be caused by shared childhood environment, further analyses after the linkage of 
environmental exposure data can be warranted. Further investigation of familial cancer 
survival should include clinical details, such as biological markers and treatment and 
behavioral factors such as (response to) genetic counselling. Further molecular or genetic 
investigations of cancer patients are necessary to gain a deeper understanding of the 
biological mechanisms behind the survival.  
My PhD project has been made possible by the infrastructure for research in Sweden, 
especially the accessibility of high-quality population-based registers. Thanks to such 
valuable resources, the results of this thesis can, I hope, leave a small footprint on the wide 
world of cancer epidemiology. Nowadays, many countries have established population-based 
registers in various fields offering more opportunities for epidemiological research to provide 
increased understanding of human diseases and help to provide better public health.  
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